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Tumor-specific neoantigens can be highly immunogenic, but their identification for each
patient and the production of personalized cancer vaccines can be time-consuming
and prohibitively expensive. In contrast, tumor-associated antigens are widely expressed
and suitable as an off the shelf immunotherapy. Here, we developed a PLGA-based
nanoparticle vaccine that contains both the immunogenic cancer germline antigen
NY-ESO-1 and an α-GalCer analog IMM60, as a novel iNKT cell agonist and dendritic cell
transactivator. Three peptide sequences (85–111, 117–143, and 157–165) derived from
immunodominant regions of NY-ESO-1 were selected. These peptides have a wide HLA
coverage and were efficiently processed and presented by dendritic cells via various HLA
subtypes. Co-delivery of IMM60 enhanced CD4 and CD8T cell responses and antibody
levels against NY-ESO-1 in vivo. Moreover, the nanoparticles have negligible systemic
toxicity in high doses, and they could be produced according to GMP guidelines.
Together, we demonstrated the feasibility of producing a PLGA-based nanovaccine
containing immunogenic peptides and an iNKT cell agonist, that is activating DCs to
induce antigen-specific T cell responses.
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INTRODUCTION
Recent advancements in cancer immunotherapy such as checkpoint blockade therapy, CAR
T cells, and neo-epitope-based RNA vaccines show that once activated, the adaptive
immune system is capable of recognizing and eradicating tumor cells (1). This recognition
is based on tumor antigens which are either normal proteins that are aberrantly or
over-expressed in tumors [tumor-associated antigens (TAA)], or proteins that are mutated
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during tumorigenesis (tumor-specific antigens or neoantigens).
While neoantigens are patient-specific, TAAs are widely
expressed in a majority of cancer patients with various types
of tumors (1). One subset of TAAs is cancer germline antigens
which are generally expressed in immune-privileged sites such
as germ cells of the testes, in fetal ovaries, and on trophoblasts
(1, 2). The immune system is thought not to be desensitized
against cancer germline- and mutated-proteins and therefore, T
cell responses can be induced against these antigens (3, 4).
Invariant Natural Killer T (iNKT) cells represent a specialized
subset of immune cells characterized by the expression of a
restricted αβ T cell antigen receptor (TCR) that specifically
recognizes lipid antigens such as α-GalCer presented by CD1d
molecules expressed by dendritic cells (DCs), macrophages and
B cells (5). Upon activation, they rapidly secrete large amounts of
cytokines and induce subsequent activation of different cell types,
including DCs, NK cells, and T cells (6). Due to the production
of cytokines (i.e., IFN-γ, IL-4) and DC activation through CD40-
CD40L interaction, iNKT cells can act as a helper T cell to boost
cytotoxic T cell (CTL) responses. Hence, α-galactosylceramide
(α-GalCer) and its analogs are explored as vaccine adjuvants (7).
NY-ESO-1 antigen has been used in clinical vaccination
studies, mainly because of its expression in a broad range
of cancers with high incidence (one-third to one-fourth of
melanoma, lung, breast, esophageal, liver, gastric, prostate,
ovarian, and bladder cancer) (8–10). Vaccinations led to an
enhancement of humoral and cellular immune responses and
clinical improvements have been documented in some patients,
supporting the role of NY-ESO-1 as an attractive antigen for
therapeutic vaccination (3, 11, 12). Moreover, the development
of potent vaccines with multiple shared tumor antigens including
NY-ESO-1 in combination with checkpoint blockade therapy has
recently been shown to enhance the clinical response rates of
cancer patients (13).
Effective cancer vaccines should induce strong and long-
lasting immune responses. Our previous preclinical data with
nanoparticle-encapsulated iNKT cell agonists (α- GalCer and
IMM60) and antigens (ovalbumin and HPV-E7) in mice
demonstrated regression of tumors after a single injection of
nanoparticles (14, 15). We observed that iNKT cell agonists have
a high adjuvant effect at dosages that could be loaded within
PLGA nanoparticles and therefore, has an advantage over TLR
ligands that could not be sufficiently loaded (14). Additionally,
activation of iNKT cells by PLGA nanoparticles led to activation
and mobilization of multiple cell types such as NK cells, B cells,
CD4, and CD8T cells as well as alternative cognate licensing
of DCs (15, 16). Moreover, we and others showed that antigen
vaccinations, together with iNKT cell agonists, provide a strong
immune response and long-lasting tumor regression if employed
in combination with checkpoint blockade therapy (15, 17).
Here we describe the design of a PLGA-based nanoparticle,
for co-delivery of NY-ESO-1 peptides with an iNKT cell agonist,
as a cancer vaccine. We selected IMM60 as an iNKT cell
agonist because of its enhanced ability to activate human
iNKT-cells compared with α-GalCer, resulting in extended
iNKT responses (18). Using NY-ESO-1-specific TCR mRNA
transfection of healthy donor T cells, and patient-derived T cells,
we confirmed previous observations that peptides are indeed
more immunogenic than the whole protein (19) and that the
selected peptides could be efficiently processed and presented
by multiple HLA types either in solution or in nanoparticle-
encapsulated form. Furthermore, we demonstrated enhanced in
vivo immune responses with nanoparticles compared to soluble
peptide injections and a further enhancement due to co-delivery
of iNKT cell agonist IMM60 within the nanoparticles.
METHODS
Reagents
PLGA (Resomer RG 502H, lactide/glycolide molar ratio
50:50) was purchased from Evonik Solvents. Dichloromethane
was obtained from Merck. CryoSure-DMSO from WAK-
Chemie. Polyvinyl alcohol 80% (PVA) from Sigma. Pure
water from Braun. Isopropyl alcohol, ≥ 99.7% ACN,
≥ 99.9%, MeOH, ≥ 99.9%, and (CHCl3, ≥ 99%) were
obtained from Sigma-Aldrich. NY-ESO-1 derived peptides;
85–111 (SRLLEFYLAMPFATPMEAELARRSLAQ), 117–
143 (PVPGVLLKEFTVSGNILTIRLTAADHR), and 157–165
(SLLMWITQC) were custom synthesized by Genscript and
Pichem; 153–167 (LQQLSLLMWITQCFL), and 97–111
(ATPMEAELARRSLAQ) was produced by Genscript. All
peptides had >95% purity and concentrations were based on
net peptide weights determined by nitrogen analysis. IMM-60
was provided by Ian Walters of iOx Therapeutics. RPMI 1,640
medium was obtained from Life Technologies. Full-length
NY-ESO-1 protein was produced in Escherichia coli by the
Ludwig Institute for Cancer Research, New York branch. 0.5mg
NY-ESO-1 protein was dissolved in 1ml water containing 240mg
urea, 3.75mg glycine, 13.8mg Sodium Dihydrogen Phosphate
Monohydrate, and 8.5mg Sodium Chloride.
Nanoparticle production
All PLGA nanoparticles (NPs) were prepared using a single
emulsion and solvent evaporation–extraction method, as
described previously (10). Briefly, 100mg of PLGA was dissolved
in 3ml of dichloromethane containing 1mg of each peptide
(Supplementary Table 3) and 150 µg IMM60 dissolved in
DMSO. This organic phase was added dropwise to 25ml
of aqueous phase containing 2.5% PVA and emulsified for
120 s using a digital probe sonicator (Branson Ultrasonics,
Danbury, CT). The organic phase was evaporated overnight
at RT while stirring, and nanoparticles were collected by
centrifugation at 10,000 rpm (13304 RCF) for 35min, washed
three times with pure water, and lyophilized. Different peptide
and IMM60 concentrations were examined and reported in the
results section.
Nanoparticle Characterization
The size and polydispersity index of the nanoparticles was
analyzed by dynamic light scattering using a Nanotrac Flex
(Microtrac). The peptide content of the NPs was determined by
HPLC analysis using a standard dilution of peptides based on
net peptide content (15). All amounts of PLGA-NPs used in this
study were calculated according to their net peptide contents
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except for the particles containing full NY-ESO-1 protein which
the content could not be determined due to high amounts of
urea and glycine contamination. IMM60 content of the NPs
was determined by a Corona Veo Charged Aerosol Detector
(CAD) coupled to a DIONEX UltiMate 3000 HPLC system
(Thermo Fischer Scientific). The NPs were dissolved in DMSO
for a complete dissolution of the components and analyzed
by CAD on an XSelect CSH C18 2.5µm 3.0 × 150mm XP
column (Waters) with VanGuard Cartridges (Waters) coupled
to a column heater (65◦C), eluents MeOH-Formic Acid-
Triethylamine (99.0/0.05/0.05 vol. %) with isocratic gradient flow
rate = 1.0 ml·min−1. The quantity of IMM60 was calculated
by interpolation of the standard calibration curves of IMM60
performed in the same way as for the NPs. The endotoxin content
of the nanoparticles was analyzed using the gel-clot method
by Eurofins PROXY laboratories, Leiden, The Netherlands, and
found to be lower than 0.1 EU/mg particles.
In vitro Antigen Presentation With TCR
mRNA Transfected T Cells
HLA typed leukapheresis products were obtained from the blood
bank Sanquin, Nijmegen, and subjected to density gradient
separation with Ficoll to obtain PBMCs. Monocytes were
isolated from PBMCs via positive MACS separation with CD14
microbeads according to the manufacturer’s protocol (Miltenyi
Biotech). The remaining cells were subjected to the untouched
separation of T cells with either the CD8T Cell Isolation Kit
or the CD4T Cell Isolation Kit according to the manufacturer’s
protocol (Miltenyi Biotech). Monocytes, CD8, or CD4T cells
were frozen in FBS 10% DMSO solution and stored in liquid
nitrogen until further use. Monocytes were thawed, and 10× 106
cells were cultured at 37◦C 5% CO2 in 8ml of full RPMI medium
(supplemented with 10% FBS, 100 U/ml penicillin, 100µg/ml
streptomycin, 2mM ultraglutamine) containing 300 U/ml IL-4
and 450 U/ml GM-CSF to generate DCs. On day 3, 3600U IL-4
and 5400U GM-CSF were added. On day 6, floating immature
DCs were harvested, and 20 × 103 cells/well were plated in
a 96 U-bottom plate. Peptides dissolved in DMSO (free form)
or encapsulated within nanoparticles were prepared in different
concentrations based on net peptide contents in full RPMI and
added to the wells. DCs were cultured with antigens for 24 h at
37◦C 5% CO2. Autologous T cells isolated from the PBMCs were
thawed, transferred to full RPMI medium containing 2µg/ml
DNase and incubated for 30min at 37◦C 5% CO2. 10ml of
PBS was added, and the cell suspension was centrifuged (8min,
300 g at room temperature). T cells were counted, 10ml of
serum-free X-VIVO 15 medium (Lonza) was added, and the cell
suspension was centrifuged for 8min, 300 g at room temperature.
Cells were resuspended in serum-free X-VIVO 15 medium in
a concentration of 40 × 106 cells/ml and transferred to 4mm
gap Gene Pulser/MicroPulser Electroporation Cuvettes (Bio-
Rad). Ten Microgram of mRNA encoding α and β chains
of TCR recognizing NY-ESO-1 was mixed with the cells and
electroporated with a single square pulse of 500V for 3ms
using a Gene Pulser Xcell Electroporation System (Bio-Rad).
Electroporated cells were transferred to a tube containing 1ml
IVS medium (IMDM GlutaMAX + 5% human AB serum) and
incubated for 2 h at 37◦C 5% CO2. 50 × 10
3 TCR transfected
T cells were added to each well of DCs. LPS was added on the
wells to a final concentration of 0.2 ug/ml. Supernatants were
collected 72 h after the establishment of DC-T cell co-cultures
and analyzed for IFN-γ by ELISA.
In vitro Antigen Presentation Assay With
Patient-Derived PBMCs
Frozen PBMCs of two patients who participated in a
clinical vaccination trial using NY-ESO-1 whole protein in
ISCOMATRIX followed by a booster with recombinant fowlpox
virus expressing NY-ESO-1 (20) were analyzed for a response
to NY-ESO-1 derived peptides. These PBMCs were previously
stimulated for 14 days in vitro with a pool of overlapping
peptides covering the entire sequence of NY-ESO-1 protein.
EBV-transformed B cells of the same patients were loaded with
peptides dissolved in DMSO (free form) or nanoparticles for
18 h. These were then used as antigen-presenting cells in co-
culture with autologous PBMCs. Separately, free form peptides
and nanoparticles were incubated with PBMCs without being
loaded to EBV transformed B cells. 5 h later, CD8 and CD4T
cells in the co-cultures were analyzed for intracellular IFN-γ
by flow cytometry. For stimulation with NY-ESO-1157−165,
HLA-A∗02:01 positive EBV-transformed B cells were loaded
with the peptide and then co-cultured with a T-cell clone (4D8)
which specifically recognizes this peptide. Intracellular IFN-γ
production was assessed by flow cytometry.
Mice and Tissues
Wild-type C57BL/6J were obtained from Charles River,
Germany. AAD mice [Immp2lTg(HLA−A/H2−D)2Enge] were
obtained from Jackson, USA. HHDmice were bred in the animal
facility of the University of Oxford. All mice were aged between
8 and 15 weeks at the start of experiments. 1G4-HHD mice
are transgenic for a mouse-human hybrid TCR m1G4 (with
the human variable domains of the human 1G4 TCR that is
specific for NY-ESO-1157−165 peptide/HLA-A2 complex). All
mice were maintained under specific pathogen-free conditions at
the Central Animal Laboratory of Radboudumc (Nijmegen, The
Netherlands, or at the animal facility of the University of Oxford,
UK). Drinking water and food were provided ad libitum. PLGA
nanoparticles were dissolved in ice-cold PBS by vortexing for 30 s
before injected via iv route at the tail vein. Blood was collected
via tail vein puncture or retro-orbital puncture during terminal
anesthesia. Spleens were isolated under sterile conditions and
stored at 4◦C in RPMI 1640 medium supplemented with 100
U/ml penicillin and 100µg/ml streptomycin until processing
for maximally 2 h. Spleens were meshed through a 100µm
cell strainer by using a syringe plunger. The cell suspension
was spun at 400 × g for 5min and resuspended in 3ml of 1x
ammonium chloride solution for the lysis of erythrocytes. After
5min of incubation at room temperature, cells were washed
with 10ml of PBS. Cells were counted by a hemocytometer and
cultured in full RPMI 1,640 medium supplemented with 50µM
2-mercaptoethanol in 96 well plates.
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In vivo Priming
F1 (HHD× C57BL/6J) mice were intravenously injected with 1.1
ug (0.6 nmol) peptide-3-LP (153–167, LQQLSLLMWITQCFL)
either in solution or encapsulated within nanoparticles mixed
with 50 ng IMM60 in solution. Twenty eight days later all
mice were boosted with iv injection of 1.1 ug peptide-3-LP in a
solution mixed with 50 ng IMM60. Eight days after the boost,
mice were euthanized, splenocytes were processed and stained
with fluorescent antibodies and tetrameric pMHC (HLA-A2/Kb
NY-ESO-1157−165) (21) to identify antigen-specific CD8T cell
frequencies. F1 (HHD× B6SJLCD45.1) mice were intravenously
injected with nanoparticles containing 2,000 ng (1.1 nmol), 100
ng (55 pmol), or 10 ng (5.5 pmol) peptide-3-LP intravenously
and 10 days later, mice were euthanized, splenocytes processed,
and stained using fluorescent antibodies and tetrameric pMHC
(HLA-A2/Kb NY-ESO-1157−165). Cells were analyzed on a BD
LSR Fortesa flow cytometer.
C57Bl/6 mice were intravenously injected with 1mg NPs
containing all three peptides (8.8 ug Peptide-1, 5.9 ug Peptide-2,
and 12 ug Peptide-3 per mg NP) with 1.2 ug IMM60 per mg NP
or (6.1 ug Peptide-1, 4.3 ug Peptide-2, and 11 ug Peptide-3 permg
NP) without IMM60 (last two rows of Supplementary Table 3B).
Seven days later, splenocytes were isolated and frozen in FBS
10% DMSO. Once thawed, splenocytes were stimulated ex vivo
with 10 uM peptides 1, 2, and 3 separately. Fourty eight hours
later, IFN-γ levels in culture supernatants were determined by
ELISA. Splenocytes were stimulated for 16 h at 37◦C/5% CO2
before the addition of BFA (Sigma) (10µg/ml) and cultured for
4 h. Cells were washed and surface stained with CD3, CD8, CD4,
and LIVE/DEAD cell stain (Invitrogen, UK). Subsequently, the
cells were washed, treated with Cytofix and Perm Wash (BD
biosciences) according to the manufacturer’s instructions, and
stained with IFN-γ-PE (BD biosciences) intracellularly.
In vivo Cytotoxicity Assay
Groups of homozygous AAD mice were intravenously injected
with nanoparticles encapsulating all three peptides with or
without IMM60 and nanoparticles only encapsulating IMM60
and peptide-3. All groups were dosed based on 6 ug peptide-3
content. Injections were repeated 28 days later or the experiment
proceeded to the next step after the first injections. Six days
after the injection, naive AAD mice splenocytes were loaded
either with peptide-3, or HPV (irrelevant) peptide and stained
with 5 uM celltrace violet, and celltrace CFSE, respectively.
Antigen-loaded splenocytes were transferred as target cells to
mice vaccinated with nanoparticles. One day later, all mice were
euthanized, and cytotoxicity in spleens was measured by flow
cytometry using the following formula:
Ratio= Irrelevant Percentage: Relevant Percentage
Percent Specific killing = [1–(non-vaccinated control
ratio/Experimental ratio)]× 100
In vivo Tumor Challenge
A group of homozygous AADmice was vaccinated intravenously
with 1mgNP (peptidemix+IMM60) containing 11.4 ug peptide-
1, 13.4 ug peptide-2, and 11.5 ug peptide-3, and 1.39 ug IMM60.
Seven months later groups of vaccinated and non-vaccinated
mice were inoculated with 2.5 × 105 1C12 sarcoma cells
expressing full-length NY-ESO-1. 1C12, a Methyl Colanthrene
(MCA)-induced murine tumor cell line, was transduced with a
NY-ESO-1 expressing lentiviral vector and cloned by limiting
dilution. The parental MCA-induced cell line was isolated from
a tumor that emerged in MCA injected (intramuscular) HHD
mice. Nine days after tumor inoculation, the vaccinated group
received a booster dose and tumor growths were recorded. Mice
that rejected the first tumors were re-challenged with 5 × 105
1C12 sarcoma cells on day 74. On day 109, all mice were
euthanized, spleens and blood were isolated. Splenocytes were ex-
vivo restimulated with different peptides, and supernatants were
collected 72 h later for IFN-γ analysis.
In vivo Toxicology
A single-species preclinical toxicology study was performed
by Charles River Laboratories (Edinburg, UK) to determine
the potential toxicity of a single intravenous (bolus) injection
of PLGA nanoparticles containing 8.8 ug Peptide-1, 5.9 ug
Peptide-2, and 12 ug Peptide-3 with 1.2 ug IMM60 per mg
NP or 6.1 ug Peptide-1, 4.3 ug Peptide-2 and 11 ug Peptide-
3 per mg NP without IMM60 in mice. One control group
received only formulation buffer, one control group received
50 mg/kg PLGA particles containing NY-ESO-1 peptides
(SRLLEFYLAMPFATPMEAELARRSLAQ, PVPGVLLKEFTVSG
NILTIRLTAADHR, SLLMWITQC), and three groups received
three dose levels (0.5, 5, and 50 mg/kg) of PLGA particles
containing IMM60 and NY-ESO-1 peptides (SRLLEFYLAMPF
ATPMEAELARRSLAQ, PVPGVLLKEFTVSGNILTIRLTAADH
R, SLLMWITQC). Fifty mice were assigned to terminal necropsy
1 day after injection to monitor toxicological parameters at
the peak level. Thirty mice were subjected to necropsy 7 days
later to monitor intercurrent mortality and recovery of initial
findings. Blood was collected, transferred into tubes containing
lithium heparin, and processed for plasma, which was analyzed
for Alanine aminotransferase (ALT), Aspartate aminotransferase
(AST), and Alkaline phosphatase (ALP). Essential organs such
as the liver, spleen, lungs, kidneys, heart, bone marrow, and
thymus were stored in fixative. Tissues were processed at Charles
River Edinburgh Ltd. PROPATH. Microscopic evaluation was
conducted by a senior veterinary pathologist on all tissues.
ELISA
Human and mouse IFN gamma uncoated ELISA Kits
(Invitrogen) were used to determine levels of IFN-γ in
serum or culture media according to product protocols. Serum
samples were diluted 1/8 −1/10 in blocking buffer before adding
to ELISA plates.
For NY-ESO-1 specific antibody detection, ELISA plates were
coated by overnight incubation with 10µg/ml NY-ESO-1 protein
or 30µg/ml NY-ESO-1 protein and 30µg/ml of each peptide
in 100 ul PBS, separately. After washing with wash buffer (PBS,
0.5% Tween-20) plates were incubated with Solution B - Blocking
Buffer (Mouse Anti-OVA IgG1 Antibody ELISA Kit 30,105,
Chondrex) for 1 h. Sera were diluted 1/100 or 1/500, added
into wells, and incubated for 2 h. The plates were incubated
for 1 h with horseradish peroxidase-conjugated anti-mouse IgG1
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(30133) or IgG2c (30293) (Chondrex) followed by the addition
of tetramethylbenzidine substrate solution (Chondrex). The
reaction was stopped by the addition of 2N H2SO4, and the
absorbance was read at 450 nm.
Statistical Analysis
Levene’s test was used to assess the homogeneity of group
variances. An unpaired t-test was used to compare the means
of two groups. For comparing more than two groups, one-way
ANOVA or Kruskal-Wallis test was used with Tukey’s or Dunn’s
post-hoc tests. GraphPad Prism version 9.0.0 for Windows was
used for all statistical analysis and figures. ∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001; and ∗∗∗∗P < 0.0001. ns, not significant. Mice were
randomly assigned to all experimental groups based on online
randomization software.
RESULTS
Peptides Derived From NY-ESO-1 Are
Functional in PLGA Nanoparticles
The long NY-ESO-1 peptides that were used in this study
contain known NY-ESO-1-derived peptide epitopes in the
context of their respective HLA alleles (peptides-1 and−2 in
Table 1) and are therefore, suitable candidates for the final
TABLE 1 | Epitopes, their binding HLA allele types, and positions in the NY-ESO-1 protein sequence.
Immunogenic epitopes of NY-ESO-1




















B*52 01 FATPMEAEL 96–104
C*12:02 FATPMEAELAR 96–106
B*07:02:01 ATPMEAELARRSLAQ 97–111










A*02:01 SLLMWITQC 157–165 157–165 9 a.a Peptide-3SLLMWITQC
DPB1*04:01/04:02 SLLMWITQCFLPVF 157–170
HLA class-I binding epitopes are in black and HLA class II-binding epitopes are in blue. The long peptide sequences present in nanoparticles are designated as peptide-1, 2, and 3.
HLA, human leukocyte antigen; NY-ESO-1, New York esophageal squamous cell carcinoma 1.
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FIGURE 1 | Dose-response curves of selected peptides (dissolved in DMSO)
obtained by TCR transfected T cell cultures in vitro. (A) CD8+ T cell response
against free peptide-1 (circle) presented by HLA-B7 is compared with the
minimal epitope 97–111 (triangle), the free form whole NY-ESO-1 protein
(square), and an irrelevant peptide (cross). (B) CD4+ T cell response against
peptide-2 (circle) presented by HLA-DRB1 is compared with the free form
whole NY-ESO-1 protein (square) and an irrelevant peptide (cross). (C) CD8+ T
(Continued)
FIGURE 1 | cell response against peptide-3 (circle) presented by HLA-A2 is
compared with the free form whole NY-ESO-1 protein (square) and an
irrelevant peptide (cross). (D) CD8+ T cell response against 157–165 epitope
presented by HLA-A2. Nanoparticles containing peptide-3 (157–165) (filled
square and triangle) or peptide-3-LP (153–167) (empty square and triangle)
with/without IMM60 are compared with nanoparticles containing the whole
NY-ESO-1 protein and IMM60 (filled circle) by total PLGA nanoparticle
concentration due to the inability to calculate encapsulation of whole
NY-ESO-1 protein. Each assay is repeated at least twice with similar results,
response curves are fitted by four or five parameter non-linear regression
analyses. Mean values are shown with SD.
nanoparticle formulation (20, 22, 23). To increase the coverage
and immunogenicity of the final product, the short peptide 157–
165 (peptide-3 in Table 1) was also included. This third peptide
was preferred at minimal length to avoid the generation of
an adjoining cryptic epitope present in the long peptide 153–
167 (peptide-3-LP) with more dominant immunogenicity (24).
Together, the selected peptides cover more than 80% of the
European population for both class-I and class-II HLA alleles and
are therefore, suitable candidates for inclusion into a nanoparticle
cancer vaccine (Supplementary Table 1) (25).
The free peptides (dissolved in DMSO) were tested for
processing and presentation by monocyte-derived DCs (moDCs)
of healthy donors to autologous T cells transfected with TCRs
derived from NY-ESO-1 specific T cells (26, 27). For peptide-
1 (85–111), CD8T cells were transfected with TCR mRNA
(NY#12) recognizing 97–111 peptide of NY-ESO-1 presented
by HLA-B∗0702 (Table 1, Supplementary Table 2A) (27). IFN-γ
production was observed after stimulation with peptide-1 (85–
111) albeit lower than after stimulation with minimal epitope
97–111 at the highest dose (Figure 1A). To test peptide-2 (117–
143), CD4T cells were transfected with TCR mRNA (NY#3)
recognizing 117–139 sequence presented by HLA-DRB1∗0101
(Table 1, Supplementary Table 2A) (27). IFN-γ production
was observed by CD4T cells in a dose-dependent manner
(Figure 1B). To test peptide-3, TCR transfected CD8T cells of
HLA-A∗0201 donors were used, and dose-dependent production
of IFN-γ was also observed with this peptide (Figure 1C). We
could not observe any considerable IFN-γ response with whole
NY-ESO-1 protein in any of the TCRs and corresponding HLA
types tested (Figures 1A–C).
To test the capacity of the manufactured nanoparticles to elicit
an immune response, nanoparticles containing whole NY-ESO-1
protein or NY-ESO-1 derived peptides were loaded onto moDCs
and cultured with TCR transfected T cells. T cells stimulated
with moDCs loaded with nanoparticles containing whole NY-
ESO-1 protein produced low levels of IFN-γ even when high
nanoparticle concentrations were used, and independent of
the TCRs (Figure 1D, Supplementary Figure 1A). In contrast,
when moDCs were loaded with nanoparticles containing either
HLA-A2.1 binding short peptide-3 (157–165) or long peptide-
3-LP (153–167) or HLA-DRB1 binding peptide-2 (117–143),
high amounts (20–160-fold for the NY-ESO-1157−165 epitope)
of IFN-γ were observed (Figure 1D). These results demonstrate
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FIGURE 2 | (A) Schematic demonstration of nanoparticles produced with different components. (B–D) Dose/IFN-γ response curves of free (dissolved in DMSO) or
nanoparticle (NP) encapsulated peptides obtained by TCR transfected T cell cultures in vitro. (B) CD8+ T cell response against peptide-1 presented by HLA-B7, (C)
CD4+ T cell response against peptide-2 presented by HLA-DRB1, and (D) CD8+ T cell response against peptide-3 presented by HLA-A2. Free peptides in solution
(circles), nanoparticles containing only one peptide (colored squares), a mixture of three peptides (empty squares), and an irrelevant peptide at the highest
concentration (cross) were shown. (E) Dose-dependent IL-2 production by DN32 mouse NKT cell hybridoma activated by IMM60 in vitro. Free IMM60 in solution
(circles), nanoparticles containing all three peptides and IMM60 (1.39 ug/mg) (empty squares), nanoparticles containing only peptide-3 and IMM60 (1.42 ug/mg)
(colored triangles) and DMSO (cross) were shown. Each dot represents the mean value of triplicate wells. Assays are performed with three different nanoparticle
batches and figures are representative of four experiments with similar results. Response curves are fitted by four or five parameter non-linear regression analyses.
Mean values are shown with SD.
that peptides derived from NY-ESO-1 are functional and more
preferable for encapsulation within PLGA nanoparticles than the
complete recombinant NY-ESO-1 protein.
All Three NY-ESO-1 Peptides and IMM60
Are Functional Within Particles
PLGAnanoparticles produced with different amounts of peptides
added per 1mg PLGA were analyzed for peptide content. As
expected, peptide content was higher in particles produced in
the presence of high amounts of peptides. The amount of
peptide that could be added during the production process was
limited by its solubility in DMSO (Supplementary Figure 2,
Supplementary Table 3).
Nanoparticles are primarily taken up by professional APCs
such as DCs and macrophages and are useful carriers to deliver
water-insoluble compounds or peptide/protein cargo which
are prone to extracellular degradation (28, 29). Encapsulation
of peptides may result in a poor release, degradation, or
inability to escape to the cytosol once taken up by APCs,
hampering cross-presentation. Therefore, antigen presentation
of the nanoparticle-encapsulated peptides was compared to
the free peptides (dissolved in DMSO). An overview of the
different nanoparticles containing NY-ESO-1 peptides used
in the study is given in Figure 2A. The IFN-γ production
by TCR-transfected CD8T cells was slightly less with the
nanoparticle encapsulated peptide-1 (85–111) compared with
free peptide-1 (Figure 2B). CD4T cell response toward peptide-
2 (117–143), already observed at a very low dose of the
peptide, was not affected by the encapsulation procedure
(Figure 2C). Further dilutions were performed with shorter
incubation times or without LPS stimulation to reduce the
response to this peptide. However, these changes also gave
rise to higher inter and intra-assay variations in low doses
with multiple nanoparticle batches and the encapsulated
peptides performed at least equal when compared to soluble
peptides (Supplementary Figures 2C,D). CD8T cell response
against peptide-3 (157–165) was also not affected (Figure 2D).
Moreover, encapsulating all three peptides together neither
affected the amount of each peptide within the nanoparticle
(Supplementary Table 3B, Supplementary Figure 2B) nor their
immunogenicity compared to the single encapsulated peptides
(Figures 2B–D).
The functionality of the iNKT cell agonist, IMM60, in PLGA
nanoparticles was analyzed by comparing the ability of free
IMM60 or encapsulated IMM60 to induce IL-2 production by
the mouse iNKT cell hybridoma DN32. Mouse JAWS-II DCs
were loaded with IMM60-containing particles or free IMM60.
No difference in IL-2 production by the mouse iNKT cells was
Frontiers in Immunology | www.frontiersin.org 7 February 2021 | Volume 12 | Article 641703
Dölen et al. PLGA Nanoparticles Containing NY-ESO-1 and IMM60
observed between the two forms of IMM60, indicating that the
nanomanufacturing process did not influence the functionality
of IMM60 (Figure 2E).
In summary, all three selectedNY-ESO-1 peptides and IMM60
are processed and presented by DCs to T cells when delivered
together in PLGA nanoparticles.
Patient-Derived T Cells Are Stimulated by
Encapsulated Peptide-Loaded Autologous
B Cells
To test a broader response, including other epitopes covered by
the selected peptides, T cells within the PBMC of two patients
(#6 and #7) that participated in a NY-ESO-1 vaccination trial
were used (20). Autologous EBV-transformed B cells loaded
with free peptides or peptide-containing PLGA nanoparticles
were used as APCs. Encapsulated peptide-1 was recognized by
CD8T cells of patient #6 (Figure 3A). This patient has the HLA-
B35 allele, which is known to present NY-ESO-1 epitopes 92–
100 and 94–104 (Table 1, Supplementary Tables 4A,B). Indeed,
CD8T cell responses against soluble peptides 85–102, 89–103,
and 93–107 covering the same epitopes were also observed
(Figure 3A) (30). No CD8T cell responses were detected in
the PBMC of patient #7 which might be explained by the
lack of MHC class I alleles known to present a NY-ESO-
1 epitope (Figure 3B, Supplementary Table 4B). CD4T cell
responses were observed in both patients. Patient #6 had CD4T
cell responses against peptide-1 and peptide-2 (Figure 3C); the
latter may correspond to a DRB1∗0101 epitope covered by
peptide-2 (Table 1). Furthermore, CD4T cell responses against
peptide-2 were also detected in patient #7, possibly presented
by DRB1∗0401 (Figure 3D, Supplementary Tables 4A,B). This
experiment was repeated by directly introducing the antigens
onto the PBMC cultures and without preloading onto autologous
B cells. The trends in response to peptides were identical
(Supplementary Figure 3A). CD8T cell responses were heavily
influenced by the lack of autologous B cells as antigen presenting
cells which can be seen by the lower values of IFN-gamma
producing cells in the latter setting (Supplementary Figure 3A).
In comparison, CD4T cell activation was less dependent on the
B cell presentation.
Peptide-3 can only bind to HLA-A2.1; therefore,
a broader response is not expected. The response to
peptide-3 was tested with a patient-derived T-cell clone
(4D8) cultured with EBV-transformed B cells as APCs.
Similar stimulation of T cells was observed with a
slightly higher activity of nanoparticle-encapsulated
peptide-3 over its soluble counterpart in lower amounts
(Supplementary Figure 3B).
Co-encapsulation of Peptides and IMM60
Enhances CD4T Cell Responses in vivo
Endogenous CD4T cell responses in wild type C57BL/6 mice
are known to generate a CD4T cell response against NY-
ESO-1 86–99 epitope (31). This sequence is also present in
peptide-1. To test the induction of T cell responses in vivo,
wild type C57BL/6 mice were injected with nanoparticles
containing the three selected peptides either with or without
IMM60. One week after a single injection, splenocytes were
restimulated with the individual peptides. As expected, IFN-y
production was only observed against peptide-1 (Figure 4A).
Strikingly, IFN-y production by CD4T cells was predominantly
observed in mice injected with particles containing IMM60,
suggesting that iNKT cells can provide help for CD4T cell
responses (Figure 4A). In conclusion, IMM60 enhanced CD4T
cell responses against NY-ESO-1 in wild type mice vaccinated
with PLGA nanoparticles containing the selected NY-ESO-1
peptides and IMM60.
Co-encapsulation of Peptides and IMM60
Enhances CD8T Cell Responses in vivo
We could not observe any specific CD8T cell response in wild
type C57BL/6 mice (Supplementary Figure 3C). Therefore, we
used both AAD and HHD mice which express a hybrid MHC
class I molecule with α1 and α2 domains of the human HLA-
A2.1 molecule fused to α3 domain of mouse H-2Db molecule. In
HHD mice, HLA-A2.1 heavy chain was covalently linked to the
human β2m light chain, denominated HHD molecule, and the
H-2 Db and mouse β2-microglobulin genes have been disrupted
preventing the expression of MHC class I Kb (as well as Class I
like molecules such as CD1d) (32). In the F1 (HHD× C57BL/6J)
generation of HHD mice, wild-type murine β2-microglobulin is
expressed, allowing for the expression of CD1d, and thus the
normal development of iNKT cells.
For experiments in HLA-A2 transgenic mice, we initially
used the longer version of peptide-3 [peptide-3-LP (153–167)]
presented by HLA-A2. This peptide induced lower IFN-γ
responses than peptide-3 (157–165) in equimolar concentrations
in vitro and both in free and nanoparticle encapsulated
forms (Supplementary Figure 4A). To test the activity of
the nanoparticles containing peptide-3-LP in vivo, adoptively
transferred NY-ESO-1157−165 specific mouse CD8T cells (m1G4)
were tested for their capacity to respond. CD8T cells were
fluorescently labeled and transferred to F1 (C57BL/6 × HHD)
mice which were vaccinated with nanoparticles the next day.
Nanoparticles containing peptide-3-LP were able to stimulate
adoptively transferred CD8T cells albeit with low sensitivity (2
nmol of the long peptide stimulated m1G4T cell, 0.1 nmol failed
to do so) (Supplementary Figure 4B).
For the induction of NY-ESO-1157−165 specific T cells from
the endogenous T cell repertoire, F1 (C57BL/6 × HHD) mice
were injected intravenously with nanoparticles containing both
peptide-3-LP as well as IMM60 or with soluble peptide-3-LP
and soluble IMM60. After 28 days, a booster injection was
given. Enhanced nanoparticle-mediated delivery of antigen was
observed (Figure 4B). When nanoparticles containing peptide-
3-LP and IMM60 were used, endogenous T cell responses could
be detected even after a single dose up to 5.5 pmol 10 days
after vaccination (Figure 4C). As a result, PLGA nanoparticles
encapsulating NY-ESO-1 peptide-3-LP and IMM60 were able to
expand endogenous antigen-specific CD8T cells recognizing the
HLA-A2 epitope.
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FIGURE 3 | IFN-γ production by PBMC samples of two patients restimulated with NY-ESO-1 derived overlapping peptides in solution or selected free peptides
(dissolved in DMSO) or nanoparticles. (A) IFN-γ positive CD8T cells in restimulated PBMCs of patient#6, (B) IFN-γ positive CD8T cells in restimulated PBMCs of
patient#7, (C) IFN-γ positive CD4T cells in restimulated PBMCs of patient#6, (D) IFN-γ positive CD4T cells in restimulated PBMCs of patient#7.
To further elucidate the role of IMM60 in CD8T cell
responses, homozygous AAD mice were used. In these mice,
β2-microglobulin is intact; therefore, they have a similar
expression of H2-Dd and HLA-A2.1 as well as other class I-
like molecules such as CD1d (33) and have functional iNKT
cells (Supplementary Figures 5A,B). AADmice were vaccinated
with nanoparticles containing all three peptides (peptide-1,
peptide-2, peptide-3) with or without IMM60 or only peptide-
3 with IMM60. After 2 monthly injections, target cells were
loaded with peptide-3, transferred to immunized mice, and
antigen-specific cytotoxicity was measured. The mice injected
with nanoparticles containing IMM60 demonstrated higher
peptide-3 specific CD8T cell cytotoxicity than in mice injected
with nanoparticles without IMM60 but a mixture of peptides
(Figure 5A). When we repeated this experiment without a
booster injection, the cytotoxic response against peptide-3 with
nanoparticles containing a peptide mixture but not IMMM60
did not show a major change. However, cytotoxic responses
against particles containing both the single and multiple peptides
with IMM60 were reduced compared to the booster regime.
Nevertheless, nanoparticles with peptide mix (containing a
mouse CD4T cell epitope) and IMM60 was superior to both the
nanoparticles without IMM60 and nanoparticles with a single
CD8T cell-specific peptide and IMM60 (Figure 5B).
Together, these results demonstrate that PLGA encapsulated
long peptides have higher CD8T cell immunogenicity in vivo
than freely administered formulations which can be further
enhanced by co-delivery of IMM60.
PLGA Nanoparticles With Peptides and
IMM60 Enhance Antibody Responses
Against NY-ESO-1
AAD mice inoculated with full-length NY-ESO-1 expressing
1C12 sarcoma tumor cells rejected the tumors spontaneously,
and T cell responses were observed in most mice
(Supplementary Figures 5C,D). Sera of these mice were
analyzed to test if the nanoparticles containing three NY-
ESO-1 peptides and IMM60 can boost antibody responses
against NY-ESO-1. Despite a similar tumor rejection in both
groups, NY-ESO-1 specific antibodies in IgG1 and IgG2c
isotypes were detected exclusively in the sera of mice injected
with nanoparticles containing three peptides and IMM60
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FIGURE 4 | Endogenous CD4 and CD8 responses obtained by nanoparticle vaccination of mice. (A) C57Bl/6 mice were intravenously injected with 1mg
nanoparticles (NP) containing all three peptides with or without IMM60. Left: 7 days later, splenocytes were isolated and restimulated separately with peptide-1,
peptide-2, or peptide-3. IFN-γ amounts in culture supernatants were determined 48 h later. Right: Splenocytes were restimulated ex-vivo either with peptide-1 or
peptide-3 and stained with CD3, CD4, and intracellularly IFN-y. IFN-y staining in non-vaccinated mouse cells is shown as a dashed line. Dots represent each mouse.
(B) F1 (HHD × C57BL/6J) mice were intravenously injected with 1.1 ug (0.6 nmol) peptide-3-LP either in solution or encapsulated within nanoparticles mixed with 50
ng IMM60 in solution. Twenty eight days later all mice were boosted with 1.1 ug peptide-3-LP in a solution mixed with 50 ng IMM60 in solution. Eight days after boost
splenocytes were isolated and stained with HLA-A2/Kb NY-ESO-1157−165 tetramers. FACS plots show the NY-ESO-1157−165 specific CD8T cells (in the square).
Unpaired t-test with Welch’s correction was used to determine statistical significance. (C) F1 (HHD × B6SJLCD45.1) mice were injected with nanoparticles containing
Peptide-3-LP and IMM60 intravenously with different doses [2 ug (1.1 nmol), 100 ng (55 pmol), or 10 ng (5.5 pmol)] and 10 days later, splenocytes were isolated and
stained with HLA-A2/Kb NY-ESO-1157−165 tetramers. Mean values are shown. Dots represent each mouse. One-way ANOVA with Tukey’s correction was used to
determine statistical significance.
(Figure 5C). When the sera of these mice were subjected to an
ELISA with peptide coated wells, almost all reactivity against
whole NY-ESO-1 protein could be reproduced with Peptide-1
(Figure 5D, Supplementary Figure 6). The B cell epitope was
also preserved within the shorter 93–107 and 97–111 peptides
(Figure 5D, Supplementary Figure 6). Since both groups were
subjected to two challenges with NY-ESO-1 expressing tumors,
injection of nanoparticles, containing both iNKT cell agonist and
NY-ESO-1 peptides, are likely to have a critical contribution to
antibody responses against NY-ESO-1.
PLGA Nanoparticles With Peptides and
IMM60 Have Reversible Side Effects in
Preclinical Toxicology Studies
The toxicity of PLGA nanoparticles containing the 3 selected
NY-ESO-1 peptides and IMM60 was tested in a preclinical
toxicology study. During the toxicology study, no unscheduled
deaths were observed. One day after injection, an increase in the
liver enzymes AST and ALT was observed, which normalized at
day 7, indicating transient liver toxicity (Figure 6). Moreover,
necropsy results showed IMM60-associated liver toxicity
Frontiers in Immunology | www.frontiersin.org 10 February 2021 | Volume 12 | Article 641703
Dölen et al. PLGA Nanoparticles Containing NY-ESO-1 and IMM60
FIGURE 5 | (A) Homozygous AAD mice were intravenously injected with
nanoparticles encapsulating 6 ug (5.5 nmol) peptide-3 either mixed with
peptide-1 and 2 [NP (Peptide mix)], mixed with peptide-1,2 and IMM60 [NP
(peptide mix+IMM60)], or only with IMM60. All mice were boosted with the
same nanoparticles on day 28. Seven days after booster injections, specific in
vivo cytotoxicity of peptide-3 loaded target cells was analyzed. Dots represent
each mouse, 3–5 mice were used per group. (B) Experiment in A is repeated
without any booster injections and peptide-3 loaded target cells were
transferred 7 days after a single injection of nanoparticles with a dose of each
containing 6 ug peptide-3. Dots represent each mouse, 3 mice were used per
group. (C) Anti-NY-ESO-1 antibody levels in the sera of AAD mice vaccinated
with NP (peptide mix+IMM60) or non-vaccinated and inoculated with 1C12
sarcoma cells expressing full-length NY-ESO-1. Serum samples were diluted
1/100 and 1/500, optical densities of duplicate wells are shown. Dots
represent each mouse. (D) Peptide specificity of anti-NY-ESO-1 antibodies in
the sera of the same AAD mice as shown in (C). Optical density of ELISA wells
indicating relative IgG1 antibody levels is shown. Bars show mean optical
density values of all mice, dots represent each mouse.
[i.e., hepatocellular necrosis, (peri)vascular mononuclear cell
infiltration, and thrombus formation] on day 1 without a dose-
response relation (Supplementary Table 5). Also, minimal/mild
pulmonary vascular mononuclear cell infiltration was observed.
On day 7, despite a low-grade granulomatous inflammation
in one mouse and minimal (peri)vascular mononuclear cell
infiltration in three mice, hepatocellular necrosis in the 50 mg/kg
subgroup was no longer recorded (Supplementary Table 6),
and thrombus formation was almost completely recovered.
Similarly, the pulmonary findings observed in 3 out of
10 mice were recovered (Supplementary Table 6). In mice
injected with nanoparticles encapsulating the 3 peptides only,
hepatocellular apoptosis/necrosis was also observed. The lesions
were, however, smaller and without thrombosis or mononuclear
cell infiltration compared to the mice injected with nanoparticles
containing IMM60.
In brief, the presence of minimal/mild thrombosis and
necrosis in the liver 1 day after nanoparticle injection was
considered to be adverse, while partial recovery of necrosis
and almost complete recovery of thrombosis were noted within
7 days.
DISCUSSION
In our previous studies, iNKT cell agonists outperformed TLR
ligands upon encapsulation in PLGA nanoparticles for the co-
delivery of antigen and adjuvant to DCs (14). Effects were
mediated by chemokines, CCL17, and CXCL9, induced by iNKT
cells during the cross-priming of CD8T cells (16). Besides,
intravenous injection of nanoparticles was necessary for a
robust anti-tumor immune response which can synergize with
checkpoint modulation (15). However, so far, mostly ovalbumin
protein was used in these studies as a model antigen. Here,
we took the next step toward clinical application by moving
to the widely expressed tumor-associated cancer germline
antigen NY-ESO-1.
NY-ESO-1 can be qualified as the most suitable TAA for an
“off the shelf ” cancer vaccine due to its leading immunogenicity
which has been reaffirmed by a recent mRNA vaccination trial
incorporating various tumor-associated antigens (13). Although
mRNAs encoding multiple full-length antigens can be easily
encapsulated within liposomes, peptide/protein antigens within
PLGA have the advantage of long-term stability and wide
storage conditions. NY-ESO-1 whole protein is known to be
poorly cross-presented when delivered to DCs in free form (19).
The cross-presentation of NY-ESO-1 is enhanced by different
formulations which were previously demonstrated to induce
specific T cell responses in clinical trials (19, 20, 34). We also
reported high T cell stimulation with nanoparticles made of the
same full-lengthNY-ESO-1 and LPS coated with polyphenol (35).
However, in this study, no considerable response with PLGA
nanoparticles encapsulating NY-ESO-1 protein was observed.
This could be due to the low solubility of the NY-ESO-1 protein
in aqueous and organic solvents which hampers encapsulation
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FIGURE 6 | Wild type C57BL/6 mice were intravenously injected either with PBS (0 mg/kg), nanoparticles containing NY-ESO-1 peptide mix (6.1 ug Peptide-1, 4.3 ug
Peptide-2, and 11 ug Peptide-3 per mg NP) (50 mg/kg NP peptide mix) or increasing doses of nanoparticles containing NY-ESO-1 peptide mix and IMM60 (8.8 ug
Peptide-1, 5.9 ug Peptide-2 and 12 ug Peptide-3 with 1.2 ug IMM60 per mg NP) 0.5, 5, 50 mg/kg NP (peptide mix+IMM60). Total IMM60 doses for a mouse
weighing 20 g were 0.012, 0.12, and 1.2 ug, respectively. Twenty-four hour and 7 days after injections Alanine aminotransferase (ALT), Aspartate aminotransferase
(AST), and Alkaline phosphatase (ALP) levels were measured in blood plasma. Five male and 5 female, 10 mice were used for each group, dots represent each
mouse, Kruskal-Wallis and Dunn’s pairwise comparisons were performed for statistical analysis. Only significant differences were shown.
and quantification. In contrast, peptides derived from NY-ESO-
1 were shown to be effective for vaccination, and higher molar
quantities of peptides could be encapsulated improving the
immunogenicity of the PLGA nanoparticle vaccine (11, 36–38).
Accordingly, we focused on immunogenic epitopes of NY-ESO-
1 and determined two NY-ESO-1 long (85–111 and 117–143)
peptides and one short (157–165) peptide which are presented
in a range of MHC class-I and MHC class-II molecules covering
more than 80% of the European population.
In a previous study, similar NY-ESO-1-derived peptides and
α-GalCer loaded onto monocyte-derived DCs induced iNKT cell
expansion and CD4T cell responses in the majority, and CD8T
cell responses in some patients (38). Besides, we also added a
third short peptide (peptide-3, 157–165) presented by the highly
prevalent HLA-A2.1 molecule, which may improve CD8T cell
response rates. The same epitope was used previously in clinical
trials but suffered from either a cryptic epitope emerging in
longer forms due to extracellular cleavage or being presented
by non-APCs in the short form (24, 39). Nanoparticle delivery
can protect peptides from extracellular cleavage until professional
APCs take them up, and spleen resident cDC1s can enhance
priming of CD8T cells by utilizing the CCL17 and CXCL9
networks (16, 40, 41). Indeed, we observed higher endogenous
CD8T cell responses against this epitope in vivo with PLGA
nanoparticles, and short peptides could also induce cytotoxic
T cell response in nanoparticle form. As expected, CD8T cell
cytotoxicity against NY-ESO-1157−165 is further enhanced by the
presence of IMM60 within the particles reaffirming our previous
findings on CD8T cell responses against ovalbumin protein and
HPV-E7 peptide (14, 15). Moreover, we observed even higher
cytotoxic T cell responses when a CD4T cell epitope is also
introduced within particles together with IMM60. This hints at a
further enhancement of iNKT cell help by CD4T cell help when
multiple epitopes are covered within the particles. Therefore,
nanoparticle-mediated peptide delivery is expected to enhance
CD8T cell responses against 157–165 epitope together with the
extended activation of human iNKT cells by the novel iNKT cell
agonist IMM60 (14, 18).
Harnessing the helper functions of iNKT cells is also known
to enhance antigen-specific CD4T cell responses (42, 43). This
was also relevant in our vaccination strategy with nanoparticles
containing NY-ESO-1 peptides in which the presence of IMM60
primed endogenous CD4T cells that were otherwise almost
absent with particles containing only peptides. Tumor cells
could also present MHC class-II epitopes of NY-ESO-1 on their
surface, and NY-ESO-1 specific CD4T cells were previously
demonstrated to induce tumor regression in melanoma patients
(44, 45). CD4T cells can play various critical roles in sustaining
an anti-tumor microenvironment, helping NK and CD8T cell
survival and cytotoxicity as well as B cell responses.
IC12 sarcoma line was transduced with a lentiviral vector
to express full-length NY-ESO-1 and was cloned based on
the highest expression of NY-ESO-1. Unfortunately, this also
increased the immunogenicity of the tumor to cause spontaneous
rejections with a visible CD8T cell response hampering the
detection of vaccine-induced T cell immunity. On the other
hand, we could demonstrate a de novo antibody response
against NY-ESO-1 protein in the IC12 sarcoma inoculated
mice which were also vaccinated with nanoparticles containing
three peptides and IMM60. Even though all mice have been
introduced with NY-ESO-1 via the sarcoma cell line twice,
the full-length antigen may not be easily accessible to the B
cells as well as the nanoparticle delivered peptides or IMM60
could be responsible for transactivating the B cells in the
vaccination group. Considering the CD4T cell responses which
were dependent on co-encapsulation of IMM60 but not the
peptides, IMM60 is likely to have a significant contribution also
to the antibody responses. INKT cells are known to provide both
cognate and non-cognate help to B cells leading to enhanced
antibody responses. Through cognate help, marginal zone B cells
can acquire the particles and present glycolipid to iNKT cells.
By contrast, by non-cognate help, DCs licensed by iNKT cells
activate the CD4 helper T cells, which facilitates B cell stimulation
(46, 47). However, further research is required to fully decipher
the mechanism of help toward B cells in the PLGA nanoparticle-
mediated peptide and agonist co-delivery settings.
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As a final step toward clinical application, the systemic toxicity
of PLGA nanoparticles containing three NY-ESO-1 peptides
and IMM60 was evaluated. Mild and mostly transient liver
toxicity was observed in mice treated with IMM60 containing
nanoparticles indicating that the toxicity is dependent on iNKT
cell activation, which is known to reside in the liver of mice
in high numbers. Considering the lower numbers of iNKT
cells in humans compared with mice, and the safety of the
iNKT cell agonist α-GalCer in previous clinical treatments,
the PLGA nanoparticle vaccines containing iNKT cell agonists
can be regarded as a safe and effective modality. We believe
that the long-term stability and a full spectrum of immunity
could also render these nanoparticles with potential use against
viral infections.
In summary, we demonstrated the feasibility to encapsulate
three NY-ESO-1-derived peptides together with IMM60 in PLGA
nanoparticles. All peptides are efficiently processed and presented
by multiple HLA types in vitro and in vivo while preserving the
potency of IMM60. Furthermore, iNKT cell help was provided
for multiple epitope-specific CD8 and CD4T cell responses,
and a de novo antibody response was observed in NY-ESO-1
positive tumor-bearing mice via PLGA nanoparticle-mediated
co-delivery. Finally, no serious adverse events occurred in
the toxicological evaluation warranting the clinical testing of
these nanoparticles.
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